Premium
ISIS 5 possibilities
Author(s) -
Hunt David
Publication year - 1993
Publication title -
australian and new zealand journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 0004-8291
DOI - 10.1111/j.1445-5994.1993.tb04762.x
Subject(s) - medicine , hirudin , antithrombotic , intensive care medicine , anticoagulant , pharmacology , surgery , thrombin , platelet
There are five major therapeutic groups for possible evaluation in the ISIS 5 trial. They include intravenous beta‐blocking agents, glucose‐insulin‐potassium (GIK) therapy, newer anticoagulant and antithrombotic agents (hirudin and Hirulog), newer thrombolytic drugs such as recombinant plasminogen activator (r‐PAJ and surfactant and emulsifying agents such as Rheothrx. Many pilot studies are underway. Selection of agents will depend on the scientific interest of collaborating hospitals as well as the agent's safety and efficacy.